Gilead Sciences Exceeds Q2 Expectations, Boosts Optimism for Seladelpar Decision

Strong Q2 Performance:
Gilead Sciences reported a solid second quarter, beating analyst expectations for both profits and revenue.

Seladelpar Decision:
The company is awaiting the FDA decision for seladelpar, a drug for primary biliary cholangitis (PBC), which is expected soon.

Financial Highlights:
Gilead's revenue and earnings exceeded forecasts, driven by growth in HIV, liver disease, and oncology treatments.

Operational Efficiency:
The company demonstrated disciplined operating expense management, leading to increased non-GAAP operating income and EPS guidance for the full year.

Strategic Moves:
Gilead acquired the seladelpar royalty from Janssen, removing its royalty obligation and enhancing its financial flexibility.

Investor Confidence:
The strong performance has boosted investor optimism ahead of the seladelpar decision, reflecting the company's strategic positioning and operational efficiency.